Science 37

Science 37 is a modern clinical research site that delivers trials directly to patients’ homes. With nationwide reach and medical licensure across all 50 states, its Direct-to-Patient Site enables sponsors to expand access, improve retention, and enroll more representative patient populations compared to relying solely on a traditional site-based approach. Science 37 operates under a single Form FDA 1572 and a central IRB, supported by centralized medical oversight, research-grade nursing, and specialized direct-to-patient clinical operations. The company has successfully completed multiple FDA inspections, resulting in FDA approvals, achieving No Action Indicated (NAI) classifications with zero Form 483 observations. With more than a decade of experience, Science 37 has supported over 200 clinical trials across Phases I–IV and observational studies. Its model consistently delivers strong performance, including approximately 86% completion rates and contributing an average of 20–30% of total study enrollment as a single site. These outcomes have been validated by the Tufts Center for the Study of Drug Development (Tufts CSDD).

Founded

2014

Company size

51-200

Headquarters

Morrisville, North Carolina, US

Funding

Post Ipo Equity